León Fernández Olga Sonia, Oru Gabriel Takon, Viebahn-Haensler Renate, López Cabreja Gilberto, Serrano Espinosa Irainis, Corrales Vázquez María Elena
Pharmacy and Food Institute, University of Havana, Havana 13603, Cuba.
Medical Society for the Use of Ozone in Prevention and Therapy, D-76473 Iffezheim, Germany.
Int J Mol Sci. 2025 May 29;26(11):5256. doi: 10.3390/ijms26115256.
Medical ozone is a redox regulator with beneficial effects in oxidative etiology diseases such as rheumatoid arthritis (RA). The aim of this study is to conduct a holistic review of different pharmacological trials involving ozone in model diseases, as well as the clinical responses of RA patients. The ROS (reactive oxygen species) involved in RA and their relationship with the main pathological pathways of this autoimmune disease are considered here. The integrative analysis of experimental results from animals with clinical findings reveals that both methotrexate (MTX) and medical ozone share common mechanisms via adenosinergic regulation. This finding enables us to propose a new pharmacological mechanism in the treatment of RA. We conclude that MTX + medical ozone combined therapy reduces ROS overproduction and the generation of proinflammatory cytokines and decreases anti-cyclic citrullinate peptide levels by a mutual mechanism involving adenosine A receptors.
医用臭氧是一种氧化还原调节剂，对类风湿关节炎（RA）等氧化病因疾病具有有益作用。本研究的目的是全面综述涉及臭氧在模型疾病中的不同药理试验，以及RA患者的临床反应。本文考虑了RA中涉及的活性氧（ROS）及其与这种自身免疫性疾病主要病理途径的关系。对动物实验结果与临床发现的综合分析表明，甲氨蝶呤（MTX）和医用臭氧通过腺苷能调节具有共同机制。这一发现使我们能够提出一种治疗RA的新药理机制。我们得出结论，MTX+医用臭氧联合疗法通过涉及腺苷A受体的共同机制减少ROS的过量产生和促炎细胞因子的生成，并降低抗环瓜氨酸肽水平。
